Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Authors: Robert J. Motzer, Bernard Escudier, Piotr Tomczak, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Stéphane Oudard, Martin Gore, Jamal Tarazi, Subramanian Hariharan, Connie Chen, Brad Rosbrook, Sinil Kim, Brian I. Rini - The Lancet 2013 cited by 745